These findings aim to provide insights into optimising CAR‐NK cell therapy for paediatric sarcomas by targeting EphA2, enhancing CAR stability, and provide insights into improving therapeutic efficacy of CAR‐NK cells for the outcomes of sarcoma patients. Here, EPHA2 is linked to sarcoma.